Skip to main content

Compugen Posts Zero Q1 Revenue Amid R&D Spending Slide and Flat Loss

NEW YORK (GenomeWeb News) — Compugen today reported it earned no revenue for the first quarter as R&D spending decreased 7 percent and net loss remained flat.
 
The company reported $200,000 in revenue for the first quarter last year.
 
Compugen said R&D spending in the quarter dipped to $2.5 million from $2.7 million year over year.
 
Net loss for the quarter increased slightly to $3.11 million from $3.09 million last year.
 
As of March 31, Compugen had $23.6 million in cash, cash equivalents, deposits, and marketable securities.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.